Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer-Reference-Cited by-同舟云学术

Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer

Published:2015-07-14 Issue:4 Volume:113 Page:585-594
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Quenel-Tueux Nathalie,Debled Marc,Rudewicz Justine,MacGrogan Gaetan,Pulido Marina,Mauriac Louis,Dalenc Florence,Bachelot Thomas,Lortal Barbara,Breton-Callu Christelle,Madranges Nicolas,de Lara Christine Tunon,Fournier Marion,Bonnefoi Hervé,Soueidan Hayssam,Nikolski Macha,Gros Audrey,Daly Catherine,Wood Henry,Rabbitts Pamela,Iggo Richard

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2015247.pdf

Reference39 articles.

1. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2 (2): 101–112.

2. Carpenter R, Doughty JC, Cordiner C, Moss N, Gandhi A, Wilson C, Andrews C, Ellis G, Gui G, Skene AI (2014) Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. Breast Cancer Res Treat 144 (3): 569–576.

3. Chia YH, Ellis MJ, Ma CX (2010) Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Cancer 103 (6): 759–764.

4. Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L, Munoz C, Vega E, Calderon MJ, Sancho B, Cortes-Funes H (2014) The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. Breast 23 (3): 201–208.

5. De Censi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, Johansson H, Lien EA, Pruneri G, Viale G, Bonanni B (2011) Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol 22 (3): 582–587.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer;Current Treatment Options in Oncology;2024-08-15

2. Chemotherapy combined with endocrine neoadjuvant therapy for hormone receptor-positive local advanced breast cancer: a case report and literature review;Frontiers in Endocrinology;2024-03-13

3. Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?;Breast Cancer Research and Treatment;2024-01-24

4. Cytomorphological Disparities in Invasive Breast Cancer Cells following Neoadjuvant Endocrine Therapy and Chemotherapy;Pathobiology;2024

5. Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer;Expert Review of Anticancer Therapy;2023-01-02